Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Universite De Versailles Saint Quentin En Yvelines has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution is currently limited to 1 distinct examiner and 1 distinct art unit. This indicates a singular focus for the university's active patent matters within the patent office's administrative structure. Such a concentrated profile suggests that the university is not currently pursuing a high volume of simultaneous patent applications across different technical groups. This allows for a focused legal strategy that targets a specific area of biotechnological research.
BAILEY CHEYENNE BUCHANAN is the busiest examiner for this portfolio, handling 1 pending office action. Since this 1 pending matter is the only active case, the university's immediate patent strategy is tied to the examination style of this specific individual. The concentration of the workload in 1 art unit suggests that the current legal efforts are focused on a specific technological niche. To move forward, the university must address the specific technical objections raised by this examiner in the Biotechnology & Pharmaceuticals sector. The outcome of this single pending action will determine the immediate success of the university's current patenting efforts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BUCHANAN, BAILEY CHEYENNE | 1 | 42.9% | +57.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18258271 | BIOMARKERS SIGNATURE(S) FOR THE PREVENTION AND EARLY DETECTION OF GASTRIC CANCER | BUCHANAN, BAILEY CHEYENNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18258271 | BIOMARKERS SIGNATURE(S) FOR THE PREVENTION AND EARLY DETECTION OF GASTRIC CANCER | BUCHANAN, BAILEY CHEYENNE | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18258271 | BIOMARKERS SIGNATURE(S) FOR THE PREVENTION AND EARLY DETECTION OF GASTRIC CANCER | BUCHANAN, BAILEY CHEYENNE | 1682 | §101§103§112 | Final Rejection | — | Pending | Jun 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUniversite De Versailles Saint Quentin En Yvelines has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Bailey Cheyenne Buchanan has the most, with 1 of Universite De Versailles Saint Quentin En Yvelines's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
